

# Complement Activation by PEO-Grafted Glass Surfaces

Argaw Kidane, Kinam Park

Purdue University, School of Pharmacy, West Lafayette, Indiana 47907

Received 1 September 1998; revised 16 March 1999; accepted 19 May 1999

**Abstract:** Activation of the complement system is one way in which the human body reacts to foreign materials that come in contact with blood. Poly(ethylene oxide) (PEO) has been used quite frequently to modify biomaterial surfaces to prevent protein adsorption and cell adhesion. Despite extensive use of PEO, however, PEO-induced complement activation has not been examined before. We examined the complement activation by PEO chains grafted to glass surfaces. PEO was grafted to trichlorovinylsilane-treated glass (TCVS-glass) by  $\gamma$ -irradiation using PEO homopolymer, Pluronic® F108 (PF108), and PEO-polybutadiene-PEO triblock copolymer (COP5000). Complement activation was assessed by measuring the plasma C3a level. Of the three polymers grafted (PEO, PF108, and COP5000), only PF108 showed significant increases in complement activation over controls. Complement C3a production on PF108-grafted glass was linearly dependent on surface concentration of grafted PF108. The C3a concentration increased from 46 ng/mL to 316 ng/mL as the surface PF108 concentration increased from 0–0.25  $\mu\text{g}/\text{cm}^2$ . Kinetics of C3a generation by PF108-grafted surfaces show that 60% of the steady state C3a concentration was generated during the first hour of plasma exposure. When the same PF108-grafted glass surface was repeatedly exposed to fresh plasma, the amount of C3a generated decreased by 70% after the first exposure. This supports the “single-hit” mechanism in complement activation. PEO homopolymer did not activate complement in bulk solution, and, thus, it appears that C3a complement activation by PF108-grafted surfaces is due to the presence of poly(propylene oxide) units. Grafting of PEO using PEO-containing block copolymers requires examination of complement activating properties of the non-PEO segment. © 1999 John Wiley & Sons, Inc. *J Biomed Mater Res (Appl Biomater)* 48: 640–647, 1999

**Keywords:** complement activation; poly (ethylene oxide) grafting; glass surfaces; Pluronic surfactants; single-hit mechanism; gamma-irradiation; plasma

## INTRODUCTION

The reaction of the human body to implantable materials is diverse and complex. Protein adsorption, cellular adhesion, and complement activation are manifestations of a myriad of reactions of the human body toward foreign materials. When a biomaterial encounters blood, protein adsorption is the first step in a series of events leading to thrombosis and failure of the biomaterial.<sup>1–5</sup> In addition, the body's recognition of implanted foreign materials begins with activation of the complement system.<sup>6</sup> The complement system is a host defense system comprising more than 20 plasma proteins. The complement system can be activated by various substances recognized as foreign to the body. Two pathways of activation of the complement system exist: the classical and the alternative pathways. Both pathways are activated by immu-

noglobulin-based stimulants (immunologic) and direct (non-immunologic) stimulants, such as polysaccharides, lipid A, and trypsin-like enzymes.<sup>7</sup> Lipopolysaccharides contain a complex polysaccharide component to which lipid A is attached. Lipopolysaccharides derived from gram negative bacteria are potent activators of the complement system and are used widely as a positive control in complement activation assays.<sup>7</sup> When the complement system is activated, a cascade of chemical reactions takes place leading to inflammation.

The relationship between surface-induced complement activation and thrombosis is not clear, but there have been claims that complement activation promotes thrombosis by enhancing cellular adhesion, platelet aggregation, and platelet activation.<sup>8–11</sup> Complement activation is also suspected of causing reduction of platelets in the circulation, due possibly to its enhancement of platelet aggregation.<sup>12</sup> Complement activating surfaces attract neutrophils and leukocytes that release chemicals such as histamine that promote platelet adhesion and aggregation.<sup>9</sup> Platelet aggregation and consumption are observed in parallel with complement activation in platelet concentrates stored following standard blood-banking procedures.<sup>12</sup> In addition, aggregation and adhesion

Correspondence to: Dr. Kinam Park, Purdue University, School of Pharmacy, West Lafayette, IN 47907-1336 (e-mail: esp@omni.cc.purdue.edu)

Contract grant sponsor: National Institutes of Health; contract grant number: HL-39081

© 1999 John Wiley & Sons, Inc.

CCC 0021-9304/99/050640-08

of platelets onto poly(methyl methacrylate) (PMMA) and nylon-6,6 surfaces were found to be significantly lower when exposed to de complemented blood compared to the same material exposed to normal blood.<sup>9</sup> Dog experiments with vascular grafts modified with various polymers showed that those surfaces causing more complement activation were also more thrombogenic, and that infusion of a de complementing compound resulted in marked decreases in thrombogenesis.<sup>8</sup>

Although many investigators have examined complement activation using a wide variety of biomaterials,<sup>8,9,13-18</sup> systematic studies of complement activation by poly(ethylene oxide) (PEO)-grafted surfaces have not been reported. PEO grafting is known to prevent protein adsorption and platelet adhesion *in vitro*.<sup>19-22</sup> *Ex vivo* studies, however, have shown that PEO grafting may not render blood contacting biomaterials nonthrombogenic.<sup>20,23</sup> Thrombus formation on PEO grafted biomaterials in *ex vivo* and *in vivo* experiments is commonly observed.<sup>23,24</sup> Since PEO-grafting has been used as one of the major approaches for making surfaces biocompatible,<sup>25-28</sup> it is important to examine the complement activating potential of PEO-grafted surfaces. This may provide new information necessary to understand differences in results between *in vitro* and *ex vivo* (or *in vivo*) studies.

## MATERIALS AND METHODS

### PEO Grafting

Glass coverslips (#1 thickness, Bellco Glass Inc., Vineland, NJ) were cleaned by soaking in a 50:50 mixture of chromic acid and sulfuric acid overnight and washed extensively with running distilled, deionized water (DDW). They were dried in a 60°C oven. Clean glass coverslips were coated with trichlorovinylsilane (Aldrich, Milwaukee, WI) following a procedure used previously in our laboratory.<sup>29</sup> Briefly, clean glass coverslips were immersed in a 5% solution of trichlorovinylsilane (Aldrich, Milwaukee, WI) in chloroform (analytical grade, Mallinkrodt, Paris, KY) for 3 h. Trichlorovinylsilane-treated glass (TCVS-glass) coverslips were rinsed with chloroform and ethanol in sequence twice followed by a copious amount of DDW before drying and curing at 60°C. TCVS-glass coverslips were stored covered at room temperature until use.

PEO was grafted to the TCVS-glass surfaces using Pluronic® F108 (PF108) (BASF, Parsippany, NJ), PEO-polybutadiene-PEO triblock copolymer (COP5000), and PEO homopolymer (PEO2000) [molecular weight = 2,000 (1,900–2,200), >95% purity, Fluka Chemical Co., Ronkonkoma, NY] (Table I). COP5000 with PEO chains of molecular weight of 5,000 was synthesized in our laboratory. PEO-grafting and surface characterization are described in our previous publications.<sup>19,25,28-33</sup>

Solutions of PF108, COP5000, and PEO2000 were prepared in DDW at concentrations ranging from 0.01–10 mg/mL. TCVS-glass coverslips were exposed to these polymer solutions in disposable glass culture tubes (16 mm × 100

**TABLE I. Polymers Used for PEO Grafting on Vinylsilane Coated Glass Coverslips<sup>a</sup>**

Polymer	Structure	Mol. Wt. (g/mL)
PF108	PEO-PPO-PEO	14,600
COP5000	PEO-PB-PEO	10,700
PEO2000	PEO	2,000

<sup>a</sup> PF108: Pluronic® surfactant F108 with (ethylene oxide)<sub>128</sub>-(propylene oxide)<sub>54</sub>-(ethylene oxide)<sub>128</sub>, where the subscripts indicate the number of repeating units. PEO: poly(ethylene oxide). PPO: poly(propylene oxide). PB: polybutadiene.

mm, Pyrex®, Corning Inc., Corning, NY). Care was taken to ensure that both faces and edges of coverslips were exposed to the grafting polymer solutions. After 1 h of adsorption, the polymer-adsorbed coverslips were exposed to  $\gamma$ -radiation from a <sup>60</sup>Co source in the presence of DDW (grafting condition A) or in the presence of bulk aqueous polymer solution (grafting condition B) for a total radiation dose of 0.8 Mrad. After  $\gamma$  irradiation, glass coverslips were soaked in 1% SDS solution overnight and rinsed thoroughly with running DDW for 3 min to remove noncovalently attached polymer molecules. Our previous study showed that the attached PEO remained on the surface after treatment with SDS and extensive rinsing.<sup>28-30</sup> The PEO-grafted glass coverslips were dried at 60°C overnight and used for complement activation experiments within two days.

### Surface Density of Grafted PEO Chains

PF108 was radio-labeled using a method described previously.<sup>32</sup> Briefly, the terminal hydroxyl groups of PEO chains on PF108 were reacted with a 5-fold molar excess of *p*-methoxyphenylchloroformate (MPC, Aldrich, Milwaukee, WI) in acetonitrile for 48 h at room temperature. The ester product (MP-PF108) was precipitated in cold anhydrous ether (analytical grade, Mallinkrodt, Paris, KY), filtered, and washed with 500 mL fresh ether twice to remove unreacted MPC. The modified polymer was then radio-labeled with <sup>125</sup>I using the Iodo-Gen reagent (Pierce Co., Rockford, IL). Radio-labeled polymer was separated from free <sup>125</sup>I by gel filtration using Sephadex® G-10 (exclusion limit of 700 Daltons, Pharmacia, Piscataway, NJ). The radio-labeled polymer was diluted with DDW to prepare adsorption solutions with concentrations ranging from 0.01–10 mg/mL. TCVS-glass capillaries were injected with the polymer solutions and adsorption was allowed to continue for 1 h at room temperature. They were then rinsed with DDW to remove excess polymer and the surface-bound radioactivity was determined with a  $\gamma$ -scintillation counter (Gamma 5500B®, Beckman, Arlington Heights, IL). The raw  $\gamma$  counts were divided by polymer solution specific activity and sample surface area to yield adsorption data in  $\mu\text{g}/\text{cm}^2$ .

### Complement Activation

Blood was drawn from three healthy human donors into a chilled potassium-EDTA (0.07 mL, 0.34 M K<sub>3</sub>-EDTA in a 13 mm × 100 mm tube) Vacutainer (Becton Dickinson, Franklin

Lakes, NJ) by a certified technician. Blood was not pooled, and blood from each donor was used in a separate experiment. The blood was transferred immediately into chilled 15 mL polypropylene centrifuge tubes (Corning, Corning, NY) and centrifuged at 2,000 g for 15 min at 4°C in a fixed-angle rotor centrifuge (JA21, Beckman, Arlington Heights, IL). The separated plasma was used immediately within 1 h.

A lipopolysaccharide (LPS) from *E. coli*, (Serotype 0111: B4, Sigma, St. Louis, MO), a potent complement activator, was used as a positive control. The effect of concentration of LPS on the extent of complement activation was examined. LPS was mixed with plasma in a sterile tissue culture polystyrene multiwell plate (Falcon, #3047, Becton Dickinson, Franklin Lakes, NJ) to give final concentrations of LPS in plasma ranging from 1–52 mg/mL. The multiwell plate was incubated at room temperature for 1 h. Plasma samples were removed and examined for complement activation by measuring the C3a concentration using a commercial human complement C3a des Arg <sup>125</sup>I assay system (Amersham Life Sciences, Arlington Heights, IL). A concentration of LPS that gave an optimum degree of complement activation was chosen and used as a positive control.


PEO-grafted glass coverslips (circular, #1 thickness, 1.2 cm diameter) were hydrated with normal saline (Sigma, St. Louis, MO) for 1 h in a sterile multiwell plate prior to exposure to plasma. One milliliter of plasma was placed into each well. Samples used were glass coverslips grafted with PF108, COP5000, or PEO 2000. Glass and TCVS-glass coverslips were used as controls. The multiwell plate was incubated at room temperature for 1 h. Plasma samples (0.45 mL) were taken and assayed for C3a levels.

#### Kinetics of Complement Activation

Kinetics of complement activation by PEO-grafted surfaces were examined using glass grafted with PF108. A PF108 solution (concentration of 10 mg/mL in DDW) was used for grafting TCVS-glass coverslips (#1 thickness, 9 mm × 22 mm). PF108-adsorbed glass coverslips were gamma-irradiated in the presence of PF108 solution (total radiation dose of 0.8 Mrad), washed with 1% sodium dodecylsulfate (SDS) and rinsed with DDW before drying at 60°C overnight. The surface PEO chain concentration was determined by <sup>125</sup>I-labeled experiments to be 0.25 μg/cm<sup>2</sup>. PF108-grafted surfaces were exposed to plasma and incubated at room temperature. Plasma samples (0.45 mL) were taken at timed intervals up to 48 h post-exposure and assayed immediately for C3a.

#### Effect of Repeated Exposure to Fresh Plasma

Glass coverslips (#1 thickness, 9 mm × 35 mm), grafted with PF108 at a surface PEO concentration of 0.25 μg/cm<sup>2</sup>, was hydrated with normal saline (0.9% NaCl solution) for 1 h. Normal saline was replaced with plasma and incubated for 1 h at room temperature. Plasma-exposed coverslips were rinsed briefly with normal saline and placed in fresh plasma



**Figure 1.** Concentration of C3a generated as a function of lipopolysaccharide (LPS) concentration added to human plasma. LPS from *E. coli* was added to fresh human plasma and incubated for 1 h at room temperature.  $n = 3$ , mean  $\pm$  S.D. C3a was measured using a commercial RIA kit.

every hour. Plasma samples were taken for analysis every hour up to 4 h.

#### Complement Activation by Solution-Phase Polymers


Solutions of PF108, COP5000, and PEO2000 were prepared in concentrations twice the desired final concentrations. Final polymer concentrations after mixing with fresh plasma ranged from 0.7–714 μM. One milliliter of each PEO solution was placed in a well in a multiwell plate and mixed with 1 mL of fresh plasma. The multiwell plate was incubated at room temperature for 1 h. Plasma samples (0.45 mL) were taken and assayed for C3a.

## RESULTS

#### Complement Activation by PEO-Grafted Glass Surfaces

The amount of C3a generated by the added lipopolysaccharide (LPS) in human plasma was linearly dependent on the concentration of LPS added over the range of 1–51.8 mg/mL (Fig. 1). The amount of C3a generated in control plasma alone was subtracted from each value to distinguish the influence of LPS on C3a generation (i.e., complement activation).

Figure 2 shows complement activation detected on control glass surfaces and surfaces grafted with PEO, PF108, and COP5000 under two different grafting conditions. Background C3a level in the plasma incubation control (Control I in Fig. 2) was 337.1  $\pm$  45.3 ng/mL. The background level of plasma C3a, as determined for a total of 57 normal human



**Figure 2.** Concentration of C3a generated by control and PEO-grafted glass surfaces. Controls I, II, and III are plasma incubation alone, with TCVS-glass, and with TCVS-glass subjected to  $\gamma$ -irradiation, respectively. Bulk grafting polymer concentration was 10 mg/mL. "A" and "B" after the polymer names represent the grafting condition. Grafting conditions A and B indicate the absence and presence of polymer in bulk solution, respectively, during sample exposure to  $\gamma$ -irradiation.  $n = 3$ , mean  $\pm$  S.D.

males and females, was  $104 \pm 37$  ng/mL with a range of 47–211 ng/mL.<sup>34</sup> The value for our incubation control is higher than this reported endogenous C3a level in normal human plasma. This may be due to C3a activation by the polystyrene multiwell plate during plasma incubation. Treatment of glass with TCVS and exposure to  $\gamma$ -radiation did not change complement C3a activation significantly. TCVS-glass (Control II in Fig. 2) generated a C3a concentration of  $384.7 \pm 189.4$  ng/mL, while TCVS-glass exposed to  $\gamma$ -irradiation in the presence of DDW (Control III of Fig. 2) resulted in C3a concentration of  $321.1 \pm 109.0$  ng/mL. There were no statistical differences among these values. Glass surfaces grafted with PEO homopolymer activated complement to the similar extent as these controls. PEO homopolymer-grafted surfaces gave C3a concentrations of  $496.6 \pm 206.8$  and  $423.1 \pm 135.6$  ng/mL when grafted under conditions A and B, respectively. The C3a concentrations generated by COP5000-grafted glass were  $591.7 \pm 2.7$  and  $524.1 \pm 92.8$  ng/mL for grafting conditions A and B, respectively. Glass surfaces grafted with PF108 under Condition A gave a C3a level of  $468.5 \pm 84.7$  ng/mL, whereas surfaces grafted under Condition B generated  $733.3 \pm 101.5$  ng/mL of C3a. These differences in amounts of C3a generated between the two grafting conditions were not statistically significant ( $p > 0.1$ ) when PEO2000 and COP5000 were used for grafting. However, PF108 grafting resulted in statistically significant differences ( $p < 0.1$ ) in the amount of C3a gen-


erated depending on the grafting condition. Grafting condition B, in which samples were exposed to  $\gamma$ -radiation in the presence of polymers in bulk solution, usually results in higher surface concentration of grafted PEO chains.<sup>28,29</sup> The significant differences in complement activation observed with PF108-grafted surfaces indicate that the surface concentration of the grafted PF108 may affect the overall complement activation in certain cases. For this reason, the effect of the surface concentration of the grafted PF108 was examined in more detail.

#### Effect of the Surface PEO Concentration


Effect of the surface concentration of PF108 on complement activation is shown in Figure 3. Surface concentration of PF108 was varied from 3.9–35.1 pmol/cm<sup>2</sup>. The plasma background C3a concentration was subtracted from the total value. Complement C3a activation linearly increases with the increase in surface PF108 concentration. The C3a concentration changed from 104–375 ng/mL as the PF108 surface concentration increased from 0–0.25  $\mu$ g/cm<sup>2</sup>. It is apparent that the higher the surface PF108 concentration, the more activating the surface toward C3a.

#### Kinetics of C3a Generation

C3a generation by PF108-grafted surfaces was monitored for up to 48 h of exposure to plasma. Glass coverslips with a surface PF108 concentration of 0.25  $\mu$ g/cm<sup>2</sup> were used as the test surface. Figure 4 shows the kinetics of C3a generation by the PF108-grafted surface ( $\bullet$  in Fig. 4). A rapid increase in C3a concentration was observed within 1 h of exposure



**Figure 3.** Concentration of C3a generated as a function of the surface concentration of grafted PF108. The background level C3a in plasma was subtracted to distinguish the effect of PF108 chains on C3a generation. TCVS-glass exposed to  $\gamma$ -irradiation was used as a control.  $n = 3$ , mean  $\pm$  S.D.



**Figure 4.** Kinetics of complement activation by PF108-grafted glass surfaces. The surface PF108 concentration was  $0.13 \mu\text{g}/\text{cm}^2$ . Symbols: (●) complement activation by PF108-grafted coverslip; ( $\Delta$ ) complement activation by plasma incubation control; and (○) complement activation by PF108-grafted coverslip subtracted with that of plasma incubation control.  $n = 3$ , mean  $\pm$  S.D.


followed by a slow increase reaching a plateau after 24 h. During this same time period, increases in the concentration of C3a in the plasma incubation control were also observed ( $\Delta$  in Fig. 4). To separate the effect of PF108 on complement activation, the amount of C3a generated by the control plasma sample was subtracted from the original readings of C3a concentration from the test material. Complement C3a activation by the PF108-grafted surface only (○ in Fig. 4) remained constant for the first 24 h. Thus, it appears that the surface grafted PF108 has only limited capacity to induce complement activation.

#### Repeated Exposure

To gain information on surface-grafted PF108 effects on complement activation, the same PF108-grafted surface was exposed to fresh plasma repeatedly. Plasma was replaced with fresh plasma every hour up to 4 h. Figure 5 shows that the PF108-grafted surface decreases C3a formation substantially upon repeated exposure to fresh plasma. To separate the effects of the surface-grafted PF108, C3a generated by the control plasma ( $\Delta$  in Fig. 5) was subtracted from the total value (● in Fig. 5). The resulting net C3a level (○ in Fig. 5) generated by the first exposure to plasma was  $591 \text{ ng}/\text{mL}$ , and this value decreased to  $162.6 \text{ ng}/\text{mL}$  at the second exposure. Only a minimal C3a effect was observed by surface-grafted PF108 at the fourth plasma exposure.


#### Complement Activation by Free Polymer Molecules in Plasma

Since PEO-grafted surfaces were found to be complement activating, we investigated the ability of polymer molecules



**Figure 5.** C3a generation by a PF108-grafted coverslip during repeated exposure to fresh plasma. The surface PF108 concentration was  $0.25 \mu\text{g}/\text{cm}^2$  and incubation time was 1 h. Symbols: (●) PF108 grafted glass; ( $\Delta$ ) plasma incubation control; and (○) values of PF108-grafted glass minus plasma incubation control.  $n = 2$ .

dissolved in bulk aqueous solution to activate complement C3a as well. Solutions of PEO2000, COP5000, and PF108 in concentrations ranging from  $1.4$ – $1428.6 \mu\text{M}$  were tested for complement activation. To extract the effect of the dissolved polymer molecules, the C3a value for the incubation control was subtracted from the C3a value obtained for each polymer concentration. As shown in Figure 6, C3a concentration levels in plasma increased as bulk concentrations of PF108 and COP5000 increased. The C3a level generated by the dis-



**Figure 6.** C3a generated by (○) PF108, (□) COP5000, and ( $\Delta$ ) PEO 2000 dissolved in fresh plasma solution as a function of bulk polymer concentration. Plasma was incubated with the polymer solutions at room temperature for 1 h.  $n = 3$ , mean  $\pm$  S.D.

solved PEO2000, however, remained relatively constant near 150 ng/mL even though the PEO2000 concentration increased to 714  $\mu$ M. The difference in complement activation by PEO homopolymer (PEO2000) and PEO-containing block copolymers (PF108 and COP5000) suggests that polymer chemistry in segments other than the PEO block is responsible for observed complement C3a activation.

## DISCUSSION

Blood compatibility of a biomaterial depends on the nature of interactions between blood components and the biomaterial surface. It is known that grafting hydrophilic molecules such as albumin, PEO, and heparin on biomaterial surfaces reduces protein adsorption and platelet adhesion.<sup>1,33</sup> Hydrophilic materials such as cellulose dialysis membranes, poly(hydroxyethyl methacrylate) (polyHEMA), and Sephadex<sup>®</sup> are known to activate the complement system via the alternative pathway. The alternative pathway of complement activation begins with the covalent attachment of C3b, a complement system protein, to surfaces bearing nucleophiles such as amino and hydroxyl groups.<sup>16,35</sup> Surface nucleophiles react with a labile thioester group on the C3b molecule resulting in a covalent attachment. Once bound to the surface, the C3b molecule interacts with other complement system proteins to form the C3 convertase, which augments C3 cleavage and the subsequent deposition of more C3b molecules on the activating surface. Grafting of PEO or PEO-containing polymers onto biomaterial surfaces introduces hydroxyl groups. PEO hydroxyl groups are, therefore, likely to be involved in complement activation. The flexible PEO chain extends from the surface into bulk aqueous solution making the hydroxyl group accessible for interaction with complement proteins. As shown in Figure 3, higher surface concentrations of grafted PF108 result in increased complement activation. Increased concentrations of hydroxyl groups on the surface may be a contributing factor.

Generation of C3a by a complement activating surface in contact with plasma follows a "single-hit" mechanism as suggested for poly(HEMA) by Payne et al.<sup>15</sup> In this mechanism, an activating surface causes a burst in the production of C3a the first time it comes in contact with plasma. Subsequent exposures of the same surface to fresh plasma generate only a small quantity of C3a. This single-hit mechanism is consistent with the observation that hemodialysis membranes become less and less complement activating with repeated use.<sup>36</sup> We also observed that complement activation by the PF108-grafted glass follows the same "single-hit" mechanism as other complement activating surfaces. Figure 5 shows that the PF108-grafted glass, upon exposure to fresh plasma, causes an initial burst of C3a production followed by a decline in C3a generation on subsequent fresh plasma exposures. We also examined the kinetics of complement activation by PEO-grafted glass. The rate of C3a generation by the PEO-grafted surface was the highest during the first hour of exposure (Fig. 4). Maximum complement activation was

**TABLE II. Complement Activation by PEO-Grafted Surfaces Compared to Other Surfaces Known to Activate Complement**

Surface	cm <sup>2</sup> /0.5 mL Plasma	ng C3a/cm <sup>2</sup>
PEO2000-grafted glass	2.26	19
COP5000-grafted glass	2.26	41.5
PF108-grafted glass	2.26	45
Cuprophane <sup>a</sup>	5	48
Nylon oxygenator <sup>a</sup>	5	63
Zymosan <sup>a</sup>	250	48

<sup>a</sup> From Ref. 15.

observed only after the first 1 h of exposure to plasma, and this also support the "single-hit" burst mechanism of C3a generation by the PEO-grafted surfaces.

The degree of complement activation by PEO-grafted surfaces has indeed been shown to be low compared to the lipopolysaccharide positive control. However, to truly assess the significance of complement activation by PEO-grafted surfaces, it would be proper to compare them with other polymeric materials with a history of complement activation such as Cuprophane<sup>®</sup> and nylon oxygenator membranes.<sup>15</sup> Complement activation by these materials is suspected of causing complications such as pulmonary dysfunction,<sup>37</sup> hypoxemia,<sup>38</sup> and reduction of circulating platelets in the blood.<sup>12</sup> Table II shows amounts of C3a generated by PEO-grafted surfaces used in our study, as well as by nylon oxygenator membrane, Cuprophane<sup>®</sup>, and zymosan found in the literature.<sup>15</sup> Glass surfaces grafted with PEO homopolymer generated the lowest amount of C3a (19 ng/cm<sup>2</sup>), whereas COP5000- and PF108-grafted glass surfaces generated 41.5 ng/cm<sup>2</sup> and 45 ng/cm<sup>2</sup> of C3a in our assay, respectively. The C3a level generated by Cuprophane and nylon were reported to be 63 ng/cm<sup>2</sup> and 70 ng/cm<sup>2</sup>, respectively. Differences in C3a generation between the PEO homopolymer and PEO-containing block copolymers (PF108 and COP5000) indicates that factors other than hydroxyl groups may also play a role in complement activation. It is not clear at this point which groups of the hydrophobic segments of block copolymers are responsible for complement activation. It is clear, however, that PEO-containing block copolymers having shorter hydrophobic segment elicit less complement activation.

Surface-grafted PEO chains minimize protein adsorption and cell adhesion *in vitro*.<sup>1,22,39-41</sup> A solution of an individual protein is used in most *in vitro* protein adsorption experiments. Platelet-rich plasma (PRP) is used in testing platelet adhesion to PEO-grafted surfaces. These simple systems lack the complexity of the *in vivo* system. When the same PEO-grafted surfaces were tested in acute *ex vivo* experiments, no significant difference in platelet adhesion and thrombus formation was observed between PEO-grafted and control surfaces.<sup>20,23,42,43</sup> This difference between the *in vitro* and *ex vivo* results may be explained by the effect of PEO chains on the complement system. PRP used in *in vitro* platelet adhesion experiments lacks the polymorphonuclear leukocytes

that mediate the adhesion and activation of platelets on complement activating surfaces. Activation of the complement system is known to mediate chemotactic, adhesive, and phagocytic responses of polymorphonuclear leukocytes to foreign substances.<sup>9</sup> Leukocyte adhesion to complement activating surfaces is caused by the interactions of complement fragments bound to the activating surface with receptors on the leukocyte membrane.<sup>8</sup> Surface-bound leukocytes release chemicals such as platelet-activating and tissue factors.<sup>8</sup> Activation of platelets by the complement-activating factor and the initiation of coagulation by the tissue factor may play a critical role in the process of surface-induced thrombosis.<sup>8</sup> We have also shown that PEO chains grafted onto biomaterial surfaces enhance, albeit modestly, complement activation. This activation of the complement system, however modest it may be, may be enough to initiate platelet adhesion and subsequent thrombosis on biomaterial surfaces used in long-term therapy. When PEO-containing block copolymers are used for surface modification of biomaterials, complement activation can be significantly higher due to the activation by non-PEO segments of the copolymers. Thus, examination of the complement-activating properties of PEO-containing block copolymers may be necessary.

## REFERENCES

1. Andrade JD, Nagaoka S, Cooper S, Okano T, Kim SW. Surfaces and blood compatibility: Current hypotheses. *ASAIO J* 1987;33:75–84.
2. Horbett TA. Principles underlying the role of adsorbed plasma proteins in blood interactions with foreign materials. *Cardiovasc Pathol* 1993;2:137S–148S.
3. Horbett TA, Brash JL. Proteins at interfaces. In: Brash JL, Horbett TA, editors. *Proteins at interfaces. Physicochemical and biochemical studies*. Washington DC: Amer. Chem. Soc.; 1987. p 1–33.
4. Bonfield TL, Colton E, Anderson JM. Protein adsorption of biomedical polymers influences activated monocytes to produce fibroblast stimulating factor. *J Biomed Mater Res* 1992;26:457–465.
5. Han DK, Park KD, Ryu GH, Kim UY, Min BG, Kim YH. Plasma protein adsorption to sulfonated poly(ethylene oxide)-grafted polyurethane surface. *J Biomed Mater Res* 1996;30:23–30.
6. Atkins JP, Farries T. The separation of self from non-self in the complement system. *Immunol Today* 1987;8:212–215.
7. Cooper NR. Laboratory evaluation of complement activation. In: Nakamura RM, Dito WR, Tucker ES, editors. *Immunoassays: clinical laboratory techniques for the 1980s*. New York: Alan R. Liss; 1980. p 393–410.
8. Hayashi K, Fukumura H, Yamamoto N. In vivo thrombus formation induced by complement activation on polymer surfaces. *J Biomed Mater Res* 1990;24:1385–1395.
9. Herzlinger GA, Cumming RD. Role of complement activation in cell adhesion to polymer blood contact surfaces. *Trans Amer Soc Art Int Org* 1980;26:165–171.
10. Kamp KW, Oeveren WV. Contact, coagulation and platelet interaction with heparin treated equipment during heart surgery. *Int J Art Org* 1993;16:836–842.
11. Labarre DJ. Heparin-like polymer surfaces: control of coagulation and complement activation by insoluble functionalized polymers. *Int J Art Org* 1990;13:651–657.
12. Gyongyossy-Issa MI, McLeod E, Devine DV. Complement activation in platelet concentrates is surface-dependent and modulated by the platelets. *J Lab Clin Med* 1994;123:859–868.
13. Carreno MP, Maillat F, Labarre D, Jozefowicz M, Kazatchkine MD. Specific antibodies enhance Sephadex-induced activation of the alternative complement pathway in human serum. *Biomater* 1988;9:514–518.
14. Larsson R, Selen G, Bjorklund H, Fagerholm P. Intraocular PMMA lenses modified with surface-immobilized heparin: evaluation of biocompatibility in vitro and in vivo. *Biomater* 1989;10:511–516.
15. Payne MS, Horbett TA. Complement activation by hydroxyethylmethacrylate-ethylmethacrylate copolymers. *J Biomed Mater Res* 1987;21:843–857.
16. Chenoweth DE. Complement activation during hemodialysis: clinical observations, proposed mechanisms, and theoretical implications. *Artif Org* 1984;8:281–287.
17. Ikeda Y, Kohjiya S, Yamashita S, Fukumura H, Yoshikawa S. Activation of the complement system in blood on the surface of segmented polyurethane urea having good blood compatibility. *Polym J* 1988;20:273–276.
18. Gobel RJ, Janatova J, Gooze JM, Apple DJ. Activation of the complement in human serum by some synthetic polymers used for intraocular lens. *Biomater* 1987;8:285–288.
19. Amiji M, Park K. Prevention of protein adsorption and platelet adhesion on surfaces by PEO/PPO/PEO Triblock copolymers. *Biomater* 1992;13:682–692.
20. Nojiri C, Okano T, Jacobs HA, Park KD, Mohammed SF, Olsen DB, Kim SW. Blood compatibility of PEO grafted polyurethane and HEMA/styrene block copolymer surfaces. *J Biomed Mater Res* 1990;24:1157–1171.
21. Lee JH, Jeong BJ, Lee HB. Plasma protein adsorption and platelet adhesion on to comb-like PEO gradient surface. *J Biomed Mater Res* 1997;34:105–114.
22. Gombotz WR, Guanghai W, Horbett TA, Hoffman AS. Protein adsorption to poly(ethylene oxide) surfaces. *J Biomed Mater Res* 1991;25:1547–1562.
23. Grainger DW, Nojiri C, Okano T, Kim SW. In vitro and ex vivo platelet interactions with hydrophilic-hydrophobic poly(ethylene oxide)-polystyrene multiblock copolymers. *J Biomed Mater Res* 1989;23:979–1005.
24. Kidane A. PEO grafting on biomaterial surfaces using gamma-irradiation. Ph.D. Thesis, Purdue Univ, 1998.
25. Amiji M, Park K. Analysis on the surface adsorption of PEO/PPO/PEO triblock copolymers by radiolabeling and fluorescence techniques. *J App Poly Sci* 1994;52:539–544.
26. Harris JM. Poly(ethylene glycol) chemistry. Biotechnical and biomedical applications. New York: Plenum; 1992. p 385.
27. Lee JH, Kopecek J, Andrade JD. Protein-resistant surfaces prepared by PEO-containing block copolymer surfactants. *J Biomed Mater Res* 1989;23:351–368.
28. McPherson T, Kidane A, Szeifer I, Park K. Prevention of protein adsorption by tethered PEO layers: Experiments and single chain mean field analysis. *Langmuir* 1998;14:176–186.
29. McPherson TB, Shim HS, Park K. Grafting of PEO to glass, nitinol, and pyrolytic carbon surfaces by gamma irradiation. *J Biomed Mater Res App Biomat* 1997;38:289–302.
30. Tseng YC, McPherson T, Yuan CS, Park K. Grafting of ethylene glycolbutadiene block copolymers onto dimethyl-dichlorosilane-coated glass by gamma-irradiation. *Biomater* 1995;16:963–972.
31. Tseng YC, Park K. Synthesis of photo-reactive poly(ethylene glycol) and its application to the prevention of surface-induced platelet activation. *J Biomed Mater Res* 1992;26:373–391.
32. Amiji M, Park K. Surface modification by radiation induced grafting of PEO/PPO/PEO triblock copolymers. *J Colloid Interf Sci* 1993;155:251–255.

33. Amiji M, Park K. Surface modification of polymeric biomaterials with poly(ethylene oxide), albumin, and heparin for reduced thrombogenicity. *J Biomat Sci Polym Ed* 1993;4:217–234.
34. Hugli TE, Chenoweth DE. Biologically active peptides of complement: Techniques and significance of C3a and C5a measurements. In: Nakamura RM, Dito WR, Tucker ES, editors. *Immunoassays: Clinical laboratory techniques for 1980s*. New York: Alan R. Liss; 1980. p 443–460.
35. Chenoweth DE. Complement activation produced by biomaterials. *Artif Org* 1988;12:508–510.
36. Chenoweth DE. Biocompatibility of hemodialysis membranes. Evaluation with C3a anaphylatoxin radioimmunoassays. *ASAIO J* 1984;7:44–49.
37. Craddock PR, Fehr J, Brigham KL, Kronenberg RS, Jacob HS. Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. *New Eng J Med* 1977;296:769–774.
38. Backer WA, Verpooten GA, Borgonjon DJ, Vermeire PA, Linns RR, Broe ME. Hypoxemia during hemodialysis: effects of different membranes and dialysate compositions. *Kidney Int* 1983;23:738–743.
39. Fujimoto K, Inoue H, Ikada Y. Protein adsorption and platelet adhesion on to polyurethane grafted with methoxy-poly(ethylene glycol) methacrylate by plasma technique. *J Biomed Mater Res* 1993;27:1559–1567.
40. Ho CH, Limberis L, Caldwell KD, Stewart RJ. Metal-chelating pluronic for immobilization of histidine-tagged proteins at interfaces: Immobilization of firefly luciferase on polystyrene beads. *Langmuir* 1998;14:3889–3894.
41. Harper GR, Davis SS, Davies MC, Norman ME, Tadros TF, Taylor DC, Irving MP, Waters JA, Watts JF. Influence of surface coverage with poly(ethylene oxide) on attachment of sterically stabilized microspheres to rat Kupffer cells in vitro. *Biomater* 1995;16:427–439.
42. Lim F, Yu XH, Cooper SL. Effect of oligoethylene oxide monoalkyl(aryl) alcohol ether grafting on the surface properties and blood compatibility of polyurethane. *Biomater* 1993;14:537–545.
43. Goodman SL, Lelah MD, Lambrecht LK, Cooper SL, Albrecht RM. In vitro vs. ex vivo platelet deposition on polymer surfaces. *Scan Elect Micro* 1984;1:279–290.